AI assistant
Inmune Bio, Inc. — Director's Dealing 2022
Mar 23, 2022
34518_dirs_2022-03-23_34f5d855-edc0-4a90-b09a-ecbb0148bc74.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Inmune Bio, Inc. (INMB)
CIK: 0001711754
Period of Report: 2022-03-21
Reporting Person: Ganjei James Kelly (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2022-03-22 | Common Stock | A | 17793 | $8.43 | Acquired | 17793 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2022-03-21 | Option (right to buy) | $7.92 | A | 35000 | Acquired | 2032-03-20 | Common Stock (35000) | Direct |
Footnotes
F1: The purchase price of the common stock being reported is the closing price per share immediately preceding the entering into of the binding agreement to issue the securities. These shares were purchased by the Reporting Person directly from Issuer.
F2: Granted pursuant to the 2021 Stock Incentive Plan. One third (1/3) of the Option will vest at the one-year anniversary of the grant date and the remaining unvested Option will become vested and exercisable 1/24th every month thereafter until the Option is 100% vested which shall occur on the three-year anniversary of the grant date.